SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs strong Q3 results and raised outlook failed to prevent a selloff, with traders debating whether its lofty valuation had already priced in the growth and pointing to slower contract-value growth as a concern. Others see accelerating commercial AI adoption as evidence the business is executing and view the pullback as a buying opportunity.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles planned $20 billion stock-and-bond offering to fund its AI infrastructure buildout is driving the selloff, with traders focused on shareholder dilution, rising debt and whether AI demand will generate enough cash flow to justify the spending. Some see the financing as a final, previously outlined step that clears the way for Oracles AI-cloud opportunity; others worry the company is overleveraged and that returns may take too long.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys quarterly report has triggered a sharp selloff despite headline results topping expectations, as traders focus on weaker-than-expected GMV and gross profit, a forecast for gross profit growth to trail revenue growth, and valuation concerns. Some view the pullback as a buying opportunity, while bearish traders point to moderating growth and payments-mix pressure.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Reports that nonprofit Usona has submitted an FDA application for psilocybin in major depressive disorder have fueled a sharp selloff and concern that it could reach the market ahead of Compass. Traders debate whether that competition threatens COMPASSs treatment-resistant depression program, while also awaiting clarity on Compasss own NDA timeline; some question how firmly Usonas filing is confirmed.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstarts quarterly results are driving debate: traders point to stronger lending activity and renewed profitability, while skeptics focus on lowered guidance and sensitivity to interest rates and credit conditions. The mixed reaction includes short-squeeze speculation, but many remain bearish amid the stocks steep decline and concerns about debt and demand.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins third-quarter results and announcement of a new share repurchase program are driving attention. Traders welcome stronger operating income and margins, while others focus on softer same-store sales, cost pressures and the stocks persistent range-bound trading.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers quarterly earnings and revenue beat, paired with raised full-year guidance, is driving discussion, with some traders highlighting growth in newer and acquired products. Others question how durable the outlook is amid declining COVID-product sales and looming patent expirations.

Backblaze, Inc. operates as a cloud provider for businesses and consumers to store, use, and protect their data. The firm provides a foundation for businesses, developers, IT professionals, and individuals to store, backup, and archive data, host content, manage media, and build their applications. It also offers B2 Cloud Storage and Computer Backup services. The company was founded by Timothy Nufire, Gleb Budman, Charles Jones, Kwok Hang Ng, Brian Wilson, Nilay Patel and Damon Uyeda in 2007 and is headquartered in San Francisco, CA.

Backblaze Inc - Ordinary Shares - Class A

Backblazes quarterly results and raised full-year outlook have put the focus on accelerating B2 cloud-storage growth and its role in AI infrastructure. Traders welcomed the report and pushed the stock higher, while some questioned whether the momentum will last and pointed to profit-taking and broader market weakness.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiservs quarterly results came in ahead of expectations, alongside an expanded cost-savings plan and accelerated share repurchases, prompting a share-price rebound. Traders are split on whether the moves mark a genuine turnaround or a short-lived bounce, with the large impairment and lingering doubts about execution still weighing on sentiment.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,946,883.4155448. The last known price of Zcash is 1,152.25968615 USD and is down -6.04 over the last 24 hours. It is currently trading on 668 active market(s) with $1,018,436,174.86 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp rally and volatile pullback are driving debate: bullish traders are buying dips and highlighting its privacy appeal amid security concerns elsewhere in crypto, while bears warn the correction may continue. Traders also cite the anticipated NU7 network upgrade as a possible catalyst, though its impact is uncertain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG)

Bright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG) Bright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG)PR...

What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?

Does Bright Minds Biosciences Inc. (DRUG) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 97% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet

The mean of analysts' price targets for Bright Minds Biosciences Inc. (DRUG) points to a 97.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

The consensus price target hints at a 107.5% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy

Bright Minds Biosciences Inc. (DRUG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Key PointsB Group bought 67,500 shares of Bright Minds Biosciences in the first quarter...

Insider Selling: Bright Minds Biosciences (NASDAQ:DRUG) Major Shareholder Sells 109,331 Shares of Stock

Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) major shareholder Cormorant Asset Management, Lp sold 109,331 shares of the company's stock in a transaction dated Tuesday, April 28th...

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven analysts that are currently covering the stock...

Bright Minds Biosciences (NASDAQ:DRUG) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Bright Minds Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday...

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Bright Minds Biosciences Inc

Why Did DRUG Stock Rocket 51% Today?

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline.</li><li>In the Absence cohort, patients experienced a median 73.1% reduction in seizures.</li><li>The DEE cohort saw a median 63.3% decrease in major motor seizures.</li></ul>Shares of Bright Minds Biosciences Inc. (DRUG) rose over 51% on Tuesday morning, after the company announced promising topline results from its Phase 2 BREAKTHROUGH trial evaluating BMB-101.BMB-101 is a selective 5-HT2C biased agonist, in adults with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The study met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.<h2 class="st-heading-2">Trial And Participants</h2>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline, 4-week titration, and maintenance period consisting of&nbsp;2 weeks for the Absence cohort and 4 weeks for the DEE cohort.&nbsp;Participants were heavily pretreated, with a median of 3 anti-seizure medications in the Absence cohort and 5 in the DEE cohort, having failed multiple prior therapies.&nbsp;On Stocktwits, retail sentiment around the&nbsp;<a href="https://stocktwits.com/symbol/DRUG">stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_085410_png_a041b522e5.webp" alt="DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="924" height="102"><figcaption>DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Seizure Reduction</h2>In the Absence cohort, patients experienced a median 73.1% reduction in seizures lasting more than or equal to three seconds and a 74.4% decrease in total seizure time over 24 hours.&nbsp;The DEE cohort, including patients with Lennox-Gastaut Syndrome (LGS), Dravet syndrome, and Rett syndrome, saw a median 63.3% decrease in major motor seizures. LGS patients achieved a 60.3% reduction, while other DEE participants experienced a 76.1% reduction.&nbsp;Beyond seizure control, BMB-101 increased REM sleep by 90%, from 56.2 to 106.7 minutes, without altering total sleep duration.DRUG stock has gained over 93% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-arwr-stock-surge-pre-market-today/cmxwuZ6R4TS">Why Did ARWR Stock Surge Over 15% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Technician Reads Eeg Data While Subjecting The Boy To A Variety Of Visual And Respiratory Stimuli Stroboscopy.

The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.

iShares U.S. Pharmaceuticals ETF

Invesco Dynamic Pharmaceuticals ETF

VanEck Pharmaceutical ETF

SPDR Pharmaceuticals ETF

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Stocktwits Polls

$DRUG wow ,this is why you don’t hold these bios long term or over the weekend.This is a case study .

Joe Schmo

$DRUG Analysts are all over the place... 
 
-HC Wainwright reiterates Bright Minds Biosciences $145 target 
Buy 
 
-Jefferies lowers target to $110 from $145 
Buy 
 
-Baird lowers target to $107 from $126 
Outperform 
 
-BTIG lowers target to $37 from $147 
Buy

HCTI Trending! news is trending & 700k Float , 65$ price target.  
You must hate money if you ain't buying under $6 right now  
  
#LFG # $DRUG $PARA.X

OnlySqanz

$DRUG  example of a 50 bagger run that is now falling.. like clock work guys. 2/5/10/20/50 throw in $SBET for chits/giggles..

Stock Hunter

$DRUG You cant tell me they didnt know this happened in mice way before the email from the FDA ... They would of had the same results testing ...GLTA ...

Honestrick

$DRUG Tried to buy a long term call on Etrade got this message : Opening orders for this security cannot be accepted at this time.

John

$DRUG mgmt here has been really quiet for a while- didn't particpate in the fall conferences.  I guess they knew this was coming.  quite a disater for the stock.  perhaps they can overcome at some point down the road - 2028?

Aawilliam2003

$DRUG  
I set a alert when it falls below $20 after it's first spike in November 2024 and here it is

LEONARDO

Ok, I’m a dip shit green horn day trader and a covered caller. But I HAVE SEEN A PENNY STOCK JUMP FROM A buck ten to 70$ a share! Check $DRUG BABY it can happen to us too!

Steven Grandy

God I Love this board!!
FCK IT!!!! LETS GO FOR THE RECORD! ANYONE REMEMBER LITTLE STOCK CALLED $DRUG? I saw that stock shoot from a  $1.10 to over $60 bucks a share in I ONE DAY!!! It’s happened and it can HAPPEN AGAIN!!!!!

Feed

News

Sentiment

Earnings

Fundamentals

Info

DRUG Bright Minds Biosciences Inc

Fundamentals

Latest DRUG News